PDCD1 and hepatocellular carcinoma: The phase 1/2 CheckMate 040 and phase 2 keynote-224 studies have reported an objective response rate (ORR) of 14% and a median OS of 12 months for the advanced HCC patients treated with PD-1 inhibitors [11, 12].